Deciphering the molecular basis of venous thromboembolism: where are we and where should we go?

被引：12

作者：

Morange, Pierre-Emmanuel ^{[1
]}

Tregouet, David-Alexandre ^{[2
]}

机构：

[1] Univ Mediterranean, Fac Med, INSERM, UMR S626, Marseille, France

[2] Univ Paris 06, INSERM, UMR S937, Paris, France

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2010年 / 148卷 / 04期

关键词：

genetics of thrombosis and haemostasis; epidemiology; venous thrombosis; GENOME-WIDE ASSOCIATION; VON-WILLEBRAND-FACTOR; FACTOR-V-LEIDEN; ACTIVATABLE FIBRINOLYSIS INHIBITOR; QUANTITATIVE-TRAIT LOCUS; FACTOR PATHWAY INHIBITOR; COMMON GENETIC-VARIATION; COPY NUMBER VARIATION; FACTOR-XII GENE; RISK-FACTOR;

D O I：

10.1111/j.1365-2141.2009.07975.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Venous thromboembolism (VTE) is a frequent disease that has a major genetic component of risk. However, known identified genetic risk factors account for <30% of idiopathic (without any environmental origin) VTE cases. This article aims to review the lessons learnt during recent decades in the field of the genetics of VTE, describe the present state-of-art methods and discuss promising themes for finding new susceptibility loci.

引用

页码：495 / 506

页数：12

共 50 条

[1] Hormone therapies and venous thromboembolism: where are we now?
Vlieg, A. van Hylckama
Middeldorp, S.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (02) : 257 - 266
[2] Pharmacogenomics in Asthma Therapy: Where Are We and Where Do We Go?
Park, Heung-Woo
Tantisira, Kelan G.
Weiss, Scott T.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55, 2015, 55 : 129 - 147
[3] BRD in 2014: where have we been, where are we now, and where do we want to go?
Hilton, W. Mark
ANIMAL HEALTH RESEARCH REVIEWS, 2014, 15 (02) : 120 - 122
[4] Hyperhomocysteinemia in health and disease: where we are now, and where do we go from here?
Lippi, Giuseppe
Plebani, Mario
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (12) : 2075 - 2080
[5] ColVI myopathies: where do we stand, where do we go?
Allamand, Valerie
Brinas, Laura
Richard, Pascale
Stojkovic, Tanya
Quijano-Roy, Susana
Bonne, Gisele
SKELETAL MUSCLE, 2011, 1
[6] HIV-1 in Pakistan: Where we stand? Where we will go?
Khan, Sheraz
Abbas, Wasim
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2017, 67 (11) : 1730 - 1733
[7] Schistosomiasis epidemiology and control: How did we get here and where should we go?
Sturrock, RF
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2001, 96 : 17 - 27
[8] Venous Thromboembolism Prophylaxis for the General Surgical Patient: Where Do We Stand?
Petralia, Gloria A.
Kakkar, Ajay K.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 29 (01) : 83 - 89
[9] ALCOHOL AND BREAST-CANCER - WHERE ARE WE NOW AND WHERE DO WE GO FROM HERE
SCHATZKIN, A
LONGNECKER, MP
CANCER, 1994, 74 (03) : 1101 - 1110
[10] Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?
Marques, Ines Soares
Tavares, Valeria
Neto, Beatriz Vieira
Mota, Ines N. R.
Pereira, Deolinda
Medeiros, Rui
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (15)

← 1 2 3 4 5 →